Should I buy Viatris stock in 2025?

What is Viatris?

How much is the Viatris stock?

The price of Viatris stock is rising this week. As of the latest data, Viatris trades at $8.83, showing a 24-hour increase of $0.24 (+2.79%). Over the past week, the trend has moved upward, with the company boasting a market capitalisation of $10.36 billion. The average daily volume is 15.81 million shares over the last three months, with a P/E ratio at a low 3.56 and a robust dividend yield of 5.44%. Viatris’s beta stands at 0.80, indicating lower volatility than the market. With its high dividend and historically low valuation, the stock may appeal to Irish investors seeking both income and stability in their portfolios.

Our complete analysis of the Viatris stock

After a detailed review of Viatris Inc.'s latest quarterly results and an in-depth analysis of the company’s stock action over the past three years, we have leveraged proprietary models to synthesise a broad range of financial, technical, and sector data—benchmarked against a competitive global healthcare landscape. Viatris currently stands out for its unique blend of value, resilience, and sustained capital return, all while trading at metrics that signal multi-year lows on both price and sentiment. So, why might Viatris stock once again become a strategic entry point into the global pharmaceuticals sector as we approach 2025?

Recent Performance and Market Context

Viatris’s share price has experienced pronounced volatility in 2025, recently closing at $8.83, marking a session gain of +2.79%. Though the stock is currently trading towards the lower end of its 52-week range ($6.85 - $13.55), it has declined 29% year-to-date and 16.7% over the past twelve months. This substantial pullback, however, unfolds against a backdrop of the company consistently outperforming quarterly EPS estimates and executing resilient cost control and capital returns.

Importantly, the strategic context is shifting favourably for value-centric healthcare names. Global healthcare demand remains structurally robust, buoyed by ageing populations across both developed and emerging economies, increased prevalence of chronic conditions, and heightened focus on affordable access—drivers from which generics and specialty pharma providers like Viatris are optimally positioned to benefit. Additionally, recent macro pressure on US and global pharmaceutical equities has driven sector-wide de-ratings, creating what could be viewed as a fertile hunting ground for fundamentally secure, yield-generating stocks with attractive entry valuations.

• Q1 2025 results beating EPS consensus by 2% (Adjusted EPS of $0.50 vs. $0.49 expected).
• Revenue outperformance vs. estimate, despite headwinds from divestitures and legal settlements.
• Sustained capital returns of $450M YTD and a sector-leading dividend yield (5.44%).
• Strong commitment to innovation in dermatology, ophthalmology, and gastroenterology, three high-growth end-markets globally.

These factors combine to support the case for revisiting Viatris as the sector continues to adjust and consolidate.

Technical Analysis

• Relative Strength Index (RSI): Both leading readings (24.2 and 29.6) are well below the critical 30 threshold, highlighting a pronounced oversold environment not seen since 2022. Historically, such levels in large-cap, cash-generative names indicate capitulation and potential for technical mean-reversion.
• MACD: The current MACD of -0.40 may signal exhaustion of bearish momentum, particularly near the lower bound of its trading range.
• Moving Averages: While short-term MAs reflect some near-term caution (sell side bias), the long-term moving averages still signal a ‘buy’—supporting the thesis of a longer-term structural reversal taking shape.
• Key Levels: Sustained support is established at $6.85 (the 52-week low), while initial resistance is seen at $13.55 (the 52-week high), implying asymmetric upside if operational catalysts trigger a positive re-rating.
• Momentum Structure: Volume spikes during recent down-legs and stabilization at current levels are indicative of capitulation and a handover to higher-conviction, value-oriented holders.

From a short- and medium-term perspective, Viatris now combines remarkable relative value with a powerful technical recovery set-up. Entry at these levels could offer investors an attractive risk/reward profile as sentiment mean-reverts with even a modest shift in outlook.

Fundamental Analysis

• Revenue Growth: While Q1 2025 saw a reported 11% revenue decline, the divestiture-adjusted operational decline was just 2%—signalling underlying resilience. Management guidance for full-year 2025 revenue is a solid $13.75B at the midpoint, with new product revenue of $450–$550M anticipated, underscoring strong underlying portfolio progression.
• Profitability: Adjusted EBITDA guidance stands at $4.04B, with adjusted EPS at $2.23—delivering compelling cash flow in a sector where scale and financial discipline are critical.
• Valuation: Viatris stands out on value:
• P/E Ratio: At 3.56, VTRS trades at a dramatic discount to peers (Dr. Reddy's 19.04, Teva c.16).
• P/S (Price/Sales): 0.73 – indicative of significant discounted growth and/or asset value.
• P/B (Price/Book): 0.67 – the shares are priced below the book value, rare in the healthcare sector.
• Structural Strengths: The company’s mix of generics (40% of revenue) and high-recognition legacy brands (60%) ensures cash-flow durability, while diversified exposure stably anchors earnings. A global footprint (over 165 countries) and a deep bench of biosimilar launches cement a foundation for future expansion and innovation, with a scale few can match.

Through the valuation lens, Viatris stands out as an asset-backed cash generator with market-leading yield, trading below peer multiples despite consistent delivery and capital allocation discipline. This signals clear potential for multiple expansion as sentiment shifts.

Volume and Liquidity

• Average Daily Volume: At 15.81M shares (65-day average), VTRS exhibits highly liquid and efficient price discovery, limiting volatility risks and offering flexibility for both retail and institutional entry.
• Outstanding Shares: 1.17B shares outstanding, supporting ample free float for dynamic investor engagement and institutional holding capacity.
• Liquidity Structure: Short-term volatility in the context of high volume may represent a fundamental capitulation event, setting the stage for longer hold institutional repositioning and short covering.

The combination of deep liquidity, accessible free float, and a large, global shareholder base delivers a positive backdrop for dynamic valuation re-rating as key catalysts materialise.

Catalysts and Positive Outlook

• Product Innovation: Significant momentum in launching new biosimilars, generics, and complex medicines, particularly in high-growth therapeutic areas (dermatology, ophthalmology, gastroenterology).
• Operational Streamlining: Ongoing asset divestitures and cost-structure optimisation are enhancing profitability and free cash flow, positioning Viatris to reallocate capital toward higher-margin, innovation-rich segments.
• Global Expansion: Expanding penetration in emerging markets, where generic drug growth is outpacing global averages, offers a near-term growth lever.
• Regulatory and ESG Tailwinds: Shifting regulations favouring biosimilars, increased focus on affordable medicines, and ongoing ESG initiatives (including access programmes and supply chain sustainability) play directly into global healthcare mega-trends.
• Capital Allocation: Commitment to return capital via dividends (5.44% yield) and buybacks is noteworthy among large-cap pharma peers, cementing an attractive total-return proposition.

Against the backdrop of a defensive sector, Viatris is more than just a turnaround play: it is evolving into a platform for both income and growth, with multiple short- and long-term levers to drive upside.

Investment Strategies

• Short-Term Entry
• Entry near long-term support ($6.85–$8.85) is technically attractive, with the RSI indicating potentially exhausted selling and a high probability of at least a technical bounce.
• Anticipated near-term catalysts (dividend payments, upcoming product launches, and earnings surprises) provide potential for quick re-rating.
• Medium-Term Positioning
• Medium-term investors may favour holding through Q2 and Q3, capturing both dividend yield and the upside from likely incremental operational or legal risk resolution.
• As the capital return framework continues and cost reductions filter through, upside to interim targets (e.g., $11.48 for a +30% gain) becomes increasingly plausible.
• Long-Term Buy and Hold
• For longer-term allocators, Viatris’s compelling valuation, high dividend yield, and strategy of pivoting to higher-growth specialities create a strong foundation for compounded returns—even when accounting for macro and litigation risks.
• As the sector narrative shifts from price compression to innovation/reinvestment, Viatris may achieve a structurally higher valuation multiple—supported by its unique position across branded, generic, and biosimilar markets.

Across all horizons, disciplined sizing and risk management remain prudent, but the long-term risk/reward asymmetry for Viatris now tilts distinctly positive.

Is it the Right Time to Buy Viatris?

• Oversold technicals, signalling a compelling potential entry point for both near-term and patient investors.
• Rock-bottom valuation, with P/E, P/S, and P/B ratios materially below those of sector peers.
• Strong and diversified fundamentals, including robust cash flow, an elevated dividend yield, and capital-efficient product launches.
• Multiple growth catalysts on the horizon, from portfolio innovation to global expansion, driven by a world-class operating footprint and a dynamic capital return policy.
• Sector support, as healthcare and generic pharma regain favour amidst global policy, demographic, and affordability trends.

While all investments in the sector merit ongoing diligence—given headline risks and cyclical volatility—the current set-up for Viatris seems to represent an excellent opportunity for those seeking undervalued cash flow, forward-looking balance sheet strength, and a platform well-poised for multi-year compound growth.

For investors in Ireland and globally searching for resilient, high-quality healthcare names at compelling valuations, Viatris stock may be entering a new bullish phase that deserves close and renewed consideration as we move into the second half of 2025. The alignment of technical, fundamental, and market positioning makes this a potential inflection point—with the upside to drive both income and capital appreciation in the evolving pharmaceutical landscape.

How to buy Viatris stock in Ireland?

Buying Viatris (VTRS) stock online is both straightforward and secure when you use a regulated broker in Ireland. Investors can easily access Viatris shares on the NASDAQ by opening a brokerage account, typically completed in a few simple steps with ID verification and local payment methods. There are two main ways to invest: spot buying (owning the shares outright) and trading via Contracts for Difference (CFDs), which enables leveraged exposure. Each method offers distinct opportunities and risks, so understanding their differences is important. For a full comparison of trusted brokers and their fees, see the dedicated section further down this page.

Spot buying

A cash, or spot, purchase of Viatris shares means buying the stock outright on the exchange and becoming a shareholder. You benefit from exposure to share price changes and may receive dividends. Most Irish-regulated brokers charge a fixed commission per order, typically around $5–€7 (roughly €4–€6.50), regardless of the order size.

Example

The current Viatris share price is $8.83 (approx. €8.10). With a $1,000 (approx. €915) investment, you could buy about 113 shares (excluding fractional shares), including an estimated $5 brokerage fee.

Gain scenario

If the share price rises by 10%, your 113 shares would be worth $1,100. Result: that’s a $100 gross gain, or +10% on your initial investment (before taxes and possible currency conversion fees).

Trading via CFD

CFD trading allows you to speculate on Viatris share price movements without owning the actual shares. With CFDs, you can use leverage (amplifying both gains and losses), and you often have access to both rising (“long”) and falling (“short”) markets. CFD brokers typically charge via the spread (the difference between buy and sell prices) and may apply overnight financing costs if you hold leveraged positions beyond one trading day.

Example

Suppose you open a CFD position on Viatris with a $1,000 deposit and use 5x leverage. This gives you market exposure of $5,000.

Gain scenario

If the stock price rises by 8%, your position gains 8% × 5 = 40%, or $400 profit on your $1,000 margin (excluding spread and overnight costs).

Final advice

Before investing, always compare broker fees, commissions, available features, and regulatory protections. Carefully consider your financial goals and risk appetite: direct share purchase suits long-term investors seeking dividends and ownership, while CFD trading is more suitable for active traders comfortable with leverage and higher risk. Your choice should match your investment objectives and experience—use our broker comparison further down the page to help make an informed decision.

Our 7 tips for buying Viatris stock

The latest news about Viatris

Viatris stock rallied 2.79% to $8.83 amid strong technical signals and oversold market conditions. In the last week, Viatris shares have shown a notable rebound, with the Relative Strength Index (RSI) dropping as low as 24.2—an indicator of heavily oversold territory, which has historically attracted value-oriented buyers. The technical environment, despite short-term mixed signals, now points to a potential upside from current levels, with analysts suggesting a 30% medium-term target from the latest close. The stability reflected in Viatris’ beta (0.80) and its attractive 5.44% yield have also contributed to renewed market interest, standing out from other pharmaceutical names with more volatile price movements.

The company beat Q1 2025 earnings and revenue forecasts, reinforcing investor confidence in core profitability. Viatris reported adjusted EPS of $0.50 for Q1 2025, surpassing analyst expectations by over 2%. At the same time, quarterly revenues reached $3.3 billion, topping consensus forecasts with a positive surprise, even as headline results reflected softness from ongoing portfolio adjustments. Importantly for Irish and broader European markets, Viatris’ robust pipeline and continued launches of new generic drugs—totaling $67 million in new Q1 sales—underpin its status as a major supplier to health systems facing post-pandemic cost pressures.

The high and sustainable dividend yield of 5.44% offers substantial income appeal to Irish investors. Irish and European income-focused portfolios benefit from Viatris’ relatively generous dividend policy, with quarterly payments of $0.12 and an ex-dividend date as recent as May 23, 2025. Amid a challenging interest rate environment and a scarcity of high-yielding blue chips, Viatris provides dependable cash returns with a payout underpinned by resilient EBITDA and strong cash flow generation, aspects particularly sought after in the Irish market where dividend investing is increasingly favored.

Strategic focus on dermatology, ophthalmology, and gastroenterology augments Viatris’ growth prospects in the region. Viatris’ declared commitment to expand in specialty and complex biologics—key growth segments such as dermatology, ophthalmology, and gastroenterology—resonates with ongoing healthcare spending priorities announced by the Irish authorities. The company’s broad reach across more than 165 countries and strong portfolio of both biosimilars and legacy brands remain a compelling proposition for securing long-term supply agreements and hospital contracts in Ireland and throughout Europe, especially as healthcare systems seek both cost savings and access to innovative treatments.

Valuation remains deeply attractive versus sector peers, positioning Viatris as a value opportunity for Irish market participants. With a normalized price-to-earnings ratio of just 3.56—dramatically lower than the sector average and competitors like Dr. Reddy’s (19.04)—Viatris presents a compelling value case, particularly relevant to institutional investors and pension funds operating in Ireland. This gap, coupled with its secure revenue mix and ongoing capital returns to shareholders ($450 million year-to-date), signals not only stability but considerable upside potential if operational improvements and legal overhangs are resolved in coming quarters.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.